The novel model peptide, αAL14, regulates angiogenesis by inhibiting VEGFR 2-mediated signaling in HUVECs

NAN-HEE KIM1, CHANG-WON KANG1, HYE-JIN GO2, CHAN-HEE KIM2, NAM GYU PARK2 and GUN-DO KIM1

1Department of Microbiology, College of Natural Sciences, and 2Department of Biotechnology, College of Fisheries Sciences, Pukyong National University, Nam-gu, Busan 48513, Republic of Korea

Received May 10, 2016; Accepted July 7, 2016

DOI: 10.3892/ijo.2016.3651

Abstract. Inhibition of angiogenesis has been focused on as a strategy for treating several diseases including cancer. In this study, a novel model peptide αAL14 was synthesized and used to identify its inhibitory effects on angiogenesis. The anti-angiogenic effects of αAL14 were investigated using vascular endothelial cells, HUVECs. αAL14 inhibited critical angiogenic processes including tubule formation, cell migration and cell invasion with no influence on cell proliferation in HUVECs. Activity of VEGFR2 was inhibited by αAL14 treatment in HUVECs. Additionally, activities of major downstream factors of VEGFR2 such as ERK, FAK and Akt were decreased. αAL14 affected expression of Rac1, Cdc42, Arp2 and WAVE2 which are involved in formation of lamellipodia. Moreover, αAL14 reduced NF-κB that can promote expression of several genes relating to cell invasion such as MMP2 and MMP9. Therefore, the results suggest that αAL14 has a potential to be developed as anti-angiogenic drug for treating diseases driven by abnormal angiogenesis.

Introduction

Angiogenesis, making new blood vessels from existing ones, is considered as a key process in many physiological and pathological states. Many reports have demonstrated that angiogenesis is strongly implicated in cancer progression and metastasis (1,2). Research on the molecular mechanisms of angiogenesis has rapidly advanced and it has contributed to the approval of anti-angiogenic drugs for cancer (3). Recently, a large number of candidates composed of peptides have been developed because peptides have been considered as secure pharmaceutical reagents against angiogenesis-related diseases. However, there are many obstacles to synthesize optimized peptides for cancer treatment (4,5).

Raddum et al revealed that seven different model peptides based on Annexin A2 (AnxA2) present anti-angiogenic effects on HUVECs. Especially, a synthetic peptide D1-P2 adopting higher α-helical structure significantly inhibited network formation rather than the others in the co-culture system of HUVECs and SMCs (6). Therefore, in this study, in order to reveal whether peptides containing α-helical structure can affect angiogenesis, a novel cationic linear α-helical model peptide, αAL14, was used.

Therapeutic strategies for treating diseases with abnormal angiogenesis use control of VEGF receptor 2 because it can modulate main angiogenic processes such as endothelial cell proliferation, migration and tube formation by activating cellular key kinases, ERK, FAK and Akt (7,8).

Rho GTPase family members are involved in cell migration. Best-studied Rho GTPases, Rac1, Cdc42 and RhoA, contribute to extend cell protrusions at the end of cell edge, motivating cells to migrate. Formation of lamellipodia is the primary step of cell migration. During cell migration, Rac1 activates Arp2/3 complex and WAVE2 to polymerize cytoskeletal sheets at the front of cells (9,10). Like cell migration, cell invasion is triggered through degradation of ECM, secreting special proteolytic enzymes, MMPs. MMP2 and MMP9 have vital roles in the degradation of ECM during angiogenesis (11-13).

In this study, a novel α-helical model peptide αAL14 was used to identify its anti-angiogenic properties. αAL14 inhibited angiogenesis by regulating VEGFR2-mediated signaling and it affected expression of Rho GTPases (Rac1 and Cdc42)
and MMPs. Therefore, we can expect that this peptide can be applied for development of therapeutic peptides to treat angiogenesis-associated diseases such as cancer.

Materials and methods

Reagents. Matrigel was purchased from BD Bioscience (Bedford, MA, USA). Vascular endothelial growth factor (VEGF) was from Sigma-Aldrich (St. Louis, MO, USA). Formaldehyde (Junsei Chemical Co., Ltd., Tokyo, Japan), Giemsa (Gurr-Giema, BDH Merk Ltd., Poole, UK) and BrdU cell proliferation assay kit (Cell Signaling Technology, Danvers, MA, USA) were used. EGM-2 bullet kit was obtained from Lonza (Walkersville, MD, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and antibiotics (penicillin and streptomycin) were obtained from Corning (Manassas, VA, USA). Hoechst 33342 and all of rabbit primary antibodies for western blot analysis, VEGF receptor 2 (1:1,000, #9698), phospho-VEGF receptor 2 (Tyr175) (1:1,000, #2478), phospho-MEK1/2 (Ser217/221) (1:1,000, #9154), phospho-ERK1/2 (Thr202/Tyr204) (1:1,000, #4370), RhoA (1:1,000, #2117), Cdc42 (1:1,000, #2466), Rac1 (1:1,000, #2465), FAK (1:1,000, #3285), phospho-FAK (Tyr937) (1:1,000, #8556), phospho-FAK (Tyr576/77) (1:1,000, #3281), phospho-FAK (Tyr925) (1:1,000, #3284), phospho-Src (Tyr416) (1:1,000, #6943), MMP2 (1:1,000, #4022), MMP9 (1:1,000, #3852), NF-κB, phospho-NF-κB (Ser536) (1:1,000, #3033), Akt (1:1,000, #4691), phospho-Akt (Ser473) (1:1,000, #4690), mTOR (1:1,000, #2983), phospho-mTOR (Ser2481) (1:1,000, #2974), GAPDH (1:1,000, #2118) and β-actin (1:1,000, #4970) were purchased from Cell Signaling Technology Inc. and ERK2 (1:1,000, sc-6245) for western blot analysis was purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Secondary antibodies (horseradish peroxidase-conjugated anti-rabbit IgG second antibodies and anti-mouse IgG second antibodies) were purchased from Cell Signaling Technology Inc. Annexin V, Alexa Fluor® 488 Conjugate, live cell imaging solution (1X) and ProLong® Gold Antifade mounting medium were purchased from Life Technologies (Carlsbad, CA, USA).

Peptide synthesis and structure prediction. αAL14 was synthesized and purified as described (14). Briefly, αAL14 was commercially synthesized by Pepron Inc. (Daejeon, Korea) at a purity grade of >95% using N-(9-fluorenylmethoxycarbonyl) (Fmoc) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC). Synthetic peptide was dissolved in a purity grade of >95 % using N-(9-fluorenylmethoxycarbonyl) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC). Synthetic peptide was dissolved in a purity grade of >95 % using N-(9-fluorenylmethoxycarbonyl) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC). Synthetic peptide was dissolved in a purity grade of >95 % using N-(9-fluorenylmethoxycarbonyl) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC). Synthetic peptide was dissolved in a purity grade of >95 % using N-(9-fluorenylmethoxycarbonyl) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC). Synthetic peptide was dissolved in a purity grade of >95 % using N-(9-fluorenylmethoxycarbonyl) solid phase peptide synthesis with ASP48S. This peptide was purified by reverse phase high performance liquid chromatography (HPLC).

Cell culture. Human vascular endothelial cells (HUVECs) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and incubated with an endothelial basal medium-2 (EBM-2) including EGM-2 singleQuotes kit, 1% (v/v) penicillin-streptomycin and 10% (v/v) FBS.

Human keratinocytes (HaCat) and human embryonic kidney cells (HEK-293) were obtained from Korean Cell Line Bank (KCLB, Seoul, Korea). These two cell lines were incubated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% (v/v) penicillin-streptomycin and 10% (v/v) FBS. The cells were maintained at 37°C and 5% CO2 in a humidified atmosphere.

BrdU cell proliferation assay. Effects of αAL14 on cell proliferation were investigated using BrdU cell proliferation assay kit. The BrdU assay was conducted according to the manufacturer's instructions. Cells (1x10^4 cells/well) were plated on a 96-well cell culture plate and treated with αAL14 (0-40 µM) for 24 h. After incubation, cells were incubated with BrdU for 4 h at 37°C. BrdU incorporation was measured by microplate reader at 450 nm. This assay was repeated three times.

Cell adhesion assay. Cell adhesion assay was performed as described previously, with some modifications (16). The 96-well cell culture plates were coated with 50 µg/ml Matrigel and left to air dry for 1 h. Wells were blocked with 1% BSA for 1 h at room temperature and rinsed twice with 0.1% PBS before plating cells. HUVECs were suspended with complete EBM-2 media, and then seeded at 3.5x10^4 cells in each well, and then treated with various concentrations of αAL14 for 2 h at 37°C. Cells were washed twice with 0.1% PBS. The cells attached on a bottom were fixed with 4% formaldehyde for 15 min and stained with 5 mg/ml crystal violet for 10 min at room temperature. Adhesive cells were observed with phase-inverted microscope and quantitated by dye extraction with 2% SDS. The absorbance was measured at 590 nm. Experiments were performed in triplicates.

Transwell migration/invasion assay. Cell migration and invasion assay were performed as previously described, with some slight modifications (17). Briefly, Transwells with 8-µm pore size membrane (Corning, Tewksbury, MA, USA) were used to examine cell migration and invasion of HUVECs. The lower chambers were filled with EBM-2 pure medium including 20 ng/ml VEGF. HUVECs (3.5x10^4 cells/insert) suspended in EBM-2 pure medium were added on each Transwell. The Transwells and lower chambers contained αAL14 (0-20 µM). Migrated cells were measured after 24 h of incubation. Cells on topside of the membrane were removed by wiping with a cotton swab, then, the membrane was washed with 1X PBS. Cells on bottom side of the membrane were fixed with 4% formaldehyde for 15 min, and stained with 5 mg/ml crystal violet for 10 min at room temperature. Images were taken using phase-inverted microscope at a magnification of x40. To quantify migrated cells, 2% SDS was added to lysis of the cells for 1 h at room temperature and an absorbance was measured at 590 nm. To perform invasion assay, Transwells were coated with 30% Matrigel in pure EBM-2 medium and incubated for 3 h before adding cells on the inserts. Following procedure of this assay is the same with the migration assay using Transwells as above. Experiments were performed in triplicates.

Tube formation assay. The effect of αAL14 on tube formation was investigated in accordance with the procedure described by Kim et al (16). The 96-well cell culture plates were coated
with 60 µl of Matrigel per well, which was allowed to solidify at 37°C for 30 min. HUVECs were seeded at a density of 2x10^4 cells per well on the Matrigel and incubated with complete EBM-2 medium containing different concentrations of αAL14 (0-20 µM). After 18 h, tubule structures were observed using a phase-inverted microscope. Quantification of total tube length was analyzed using Wimasis image analysis service, WimTube (Wimasis GmbH, Munich, Germany). Experiments were performed in triplicates.

**Immunofluorescence staining and localization of peptide.** Immunofluorescence staining was performed as described previously with some modifications (18). Briefly, HUVECs seeded on glass coverslips were treated with 15 µM αAL14 for 30 min, fixed with 4% formaldehyde for 15 min at room temperature, and blocked with 2% BSA in PBS with 0.3% Triton X-100. These cells were then incubated with specific rabbit primary antibodies at 4°C. Phospho-VEGF receptor 2 (Tyr1175) (1:100, #2478), phospho-ERK1/2 (Thr202/Tyr204) (1:200, #4370), phospho-Akt (Ser473) (1:200, #4060) and Rac1 (1:25, #2467) were purchased from Cell Signaling Technology, Inc. and phospho-FAK (Tyr397) (1:100, sc-11765) was purchased from Santa Cruz Biotechnology, Inc. and phospho-FAK (Tyr397) (1:100, sc-11765) was purchased from Santa Cruz Biotechnology, Inc. The cells were incubated with 0.1 µg/ml of anti-rabbit IgG (H+L), F(ab')2 fragment (Alexa Fluor 488 conjugate) for 1 h at room temperature. Cells were stained with DAPI for 20 min at 37°C. After incubation, cells were treated with FITC-tagged αAL14-AL14-AL14 based on the number of amino acids in this peptide for 1 h at room temperature. The membranes were stained with FITC-PECR (1:2,000) or anti-mouse IgG second antibodies (1:2,000) for 1 h. The membranes were then washed in 1X PBST and then developed by enhanced chemiluminescence ECL® (AbFrontier, Gyeonggi, Korea). Band intensities were quantified using ImageJ.

**Reverse transcriptase PCR.** Total RNA from HUVECs (1.0x10^7 cells) was extracted using RNaseasy Mini kit (Qiagen, Venlo, KJ, The Netherlands) according to the manufacturer's protocol and quantified by Qubit (Life Technologies). RNA (1 µg) template in 20 µl reaction volume was converted into a cDNA using AccuPower® RT PreMix from Bioneer (Daejeon, Korea). cDNA (2 µl) was amplified in 20 µl reaction volume for 25 cycles. Primers for human MMP2 (forward, 5'-TTGAC GGTAAAGCAGGACTC-3' and reverse, 5'-ACTTGACGTA CTCCCCCATG-3'), human MMP9 (forward, 5'-TTGACGAC GCAGAAGAAGTTG-3' and reverse, 5'-CTTCAGTGAAGG GGTACAT-3') and human GAPDH (forward, 5'-CGGGAAA CTGTGGCGTGAT-3' and reverse, 5'-AGTGGGTGTCGCT GTGAAAGT-3'), were used. PCR product (5 µl) was run in 2% agarose gel and stained with ethidium bromide solution and band intensities were quantified using ImageJ.

**Western blot analysis.** Western blot analysis was performed as previously described with some modifications (18). Briefly, after treatments, HUVECs were washed once with cold 1X PBS and then lysed with lysis buffer containing 50 mM Tris-C1, pH 7.5, 150 mM NaCl, 1 mM DTT, 0.5% NP-40, 1% Triton X-100, 1% deoxycholate, 0.1% SDS and proteinase inhibitors (PMSF, EDTA, Aprotinin, Leupeptin, Prostatin A) (Intron Biotechnology, Gyeonggi, Korea). After 30 min on ice, lysates were centrifuged at 14,000 rpm for 20 min at 4°C to remove cell debris and collect proteins. Proteins were separated by 12% SDS-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose membrane. The membranes were blocked with 5% skim milk in 1X PBST. After blocking, the proteins were treated with primary antibodies (1:1,000) overnight at 4°C. The proteins were incubated with horseradish peroxidase-conjugated anti-rabbit IgG second antibodies (1:2,000) or anti-mouse IgG second antibodies (1:2,000) for 1 h at room temperature. The membranes were then washed in 1X PBST and then developed by enhanced chemiluminescence ECL® (AbFrontier, Gyeonggi, Korea). Band intensities were quantified using ImageJ.

**Results**

**Amphiphilic α-helical structure of αAL14.** The sequence of the novel model peptide we synthesized is AAWKLLKALAKAAL. It is composed of abundant hydrophobic and basic amino acids without disulfide bonds. According to some research (19,20), peptides including these features tend to be cationic linear amphiphilic peptides. Basic linear peptides take an amphiphilic α-helical structure and their amphipathicity presents distinct biological activities (21-23). In light of these facts, it is predicted that the synthesized peptide adopts an amphiphilic α-helical conformation because of its amino acid arrangement. According to helical wheel representation, all hydrophobic amino acid residues, A1, A2, L5, L6, A8, L9, A10, A12, A13, and L14 were located on one side, whereas hydrophilic amino acid residues, K4, K7, and K11, were located on the other side of the helix (Fig. 1). Therefore, we suggest that this peptide can be classified into the basic linear α-helical peptides and we named it as αAL14 based on the number of amino acids in this peptide and its α-helical property.

**Anti-proliferative effects of αAL14 on HUVECs.** As angiogenesis is intimately associated with endothelial cell proliferation, and most angiogenesis inhibitors affect
endothelial cell proliferation, we investigated whether αAL14 can inhibit growth of endothelial cells. HUVECs, HEK-293 cells and HaCat cells were treated with αAL14 for 24 h. In HUVECs, αAL14 did not exert an inhibitory effect on cell proliferation at ≤25 µM but cell proliferation was decreased with a statistical significance when HUVECs was incubated with >30 µM of αAL14 (Fig. 2A). In contrast, HEK-293 cells and HaCat cells were not affected by αAL14 treatment (Fig. 2A). Moreover, in order to identify whether αAL14 can trigger apoptosis in HUVECs, a marker of early apoptosis, phosphatidylserine presentation, was detected staining with Annexin V. As shown in Fig. 2B, Annexin V-positive cells were observed when HUVECs were treated with >25 µM of αAL14 for 24 h (Fig. 2B). Therefore, our data suggest that although HUVECs are more sensitive to αAL14 than the other two cell lines, αAL14 tends to show anti-proliferative effect at high concentrations. Therefore, based on this result, we used concentrations ≤20 µM of αAL14 for further studies to identify biological activities of αAL14 excluding any inhibitory effects on cell proliferation or cell survival in HUVECs.

**A localization of αAL14 in HUVECs.** As αAL14 presented hydrophobic property, we expected that this peptide penetrates...
preferentially into the cytoplasm. To prove our hypothesis, we treated HUVECs with FITC-tagged αAL14 for the indicated time period. Even though HUVECs were treated with αAL14 for a relatively short time, αAL14 rapidly internalized cytoplasm within 10 min and its FITC signal gradually increased (Fig. 3A). αAL14 was distributed throughout the cytoplasm and translocated into the nucleus when cells were treated for comparative long time (Fig. 3B). Accumulation of internalized αAL14 was increased in a dose- and temperature-dependent manner (Fig. 3C and D). However, no interactions between αAL14 and cell membrane were detected in HUVECs.

**Inhibitory effects of αAL14 in tube formation of HUVECs.** Effects of αAL14 on tubular morphogenesis of HUVECs were examined because several essential multiple steps including endothelial cell adhesion, invasion and migration are involved in tube formation (24). Incomplete discontinuous tubule structures were present in αAL14-treated HUVECs. It indicates that the formation of tubule structures was disturbed by αAL14 treatment (Fig. 4A). Consistent with this result, in quantitative analysis, total tube length decreased more than half degree in 20 µM αAL14-treated cells compared to control (Fig. 4B). Taken together, the results indicate that αAL14 is able to inhibit tubule formation on HUVECs at concentrations >15 µM.

**Effects of αAL14 on endothelial cell adhesion, migration and invasion in HUVECs.** In order to identify which steps of angiogenesis can be regulated by αAL14 treatment, effects of αAL14 on endothelial cell adhesion, migration and cell invasion were evaluated. First, inhibitory effects of
Figure 4. Effects of αAL14 on tube formation in HUVECs. (A) αAL14 decreased tubule structures. HUVECs were incubated with indicated concentration of αAL14 for 18 h on Matrigel (scale bar, 20 µm) (B) αAL14 decreased total tube length. Total tube length in each group was quantified. Each value represents mean ± SD (n=3), *p<0.001.

Figure 5. Effects of αAL14 on endothelial cell adhesion, migration and invasion. (A) αAL14 reduced adhesive ability in HUVECs. The cells were incubated with αAL14 for 2 h at 50 µg/ml in Matrigel-coated well. The cells were observed using an inverted microscope (scale bar, 250 µm, left panel). Relative endothelial cell adhesion ability was quantified. Adhesive ability was decreased in a dose-dependent manner compared to PC (NC, BSA-coated control; PC, Matrigel-coated control without peptide treatment). The data indicate the mean ± SD (n=3), *p<0.001 (right panel). (B and C) VEGF-induced endothelial cell migration and invasion were decreased by αAL14 treatment. HUVECs were incubated with various concentrations of αAL14 for 24 h. VEGF (20 ng/ml) was used as chemoattractant. Images were taken by an inverted microscope (scale bar, 250 µm, left panel). Values are mean ± SD (n=3), *p<0.001 (right panel).
αAL14 on endothelial cell adhesive ability were investigated. Adherent cells were decreased as much as negative control in 20 μM of αAL14-treated HUVECs (Fig. 5A). In Transwell migration assay, αAL14 significantly decreased VEGF-stimulated HUVEC migration (Fig. 5B). αAL14 (15 μM) reduced VEGF-stimulated cell migration about half degree compared to positive control in HUVECs. Following this, in Transwell invasion assay, αAL14 remarkably inhibited VEGF-stimulated HUVEC invasion compared to positive control (Fig. 5C). Therefore, the results suggest that αAL14 can inhibit multiple biological processes including cell adhesion, migration and invasion in endothelial cells during angiogenesis.

Effects of αAL14 on VEGFR2-mediated signaling in HUVECs. VEGF receptor 2 is a major receptor for regulating angiogenesis, which activates various downstream signaling pathways (7). In order to identify αAL14-induced anti-angiogenic effects on VEGF2-mediated signaling pathways, protein expression level of VEGFR2 was investigated. As a
result, αAL14 significantly reduced phosphorylated VEGFR2 at Tyr 1175, but did not affect total VEGFR2 protein expression (Fig. 6A). In addition, fluorescent signal of phosphorylated VEGFR2 was diminished in response to αAL14 treatment (Fig. 7A). Upon these results, we hypothesized that αAL14 is able to downregulate VEGFR2 downstream factors and we investigated expression level of VEGFR2 downstream factors including MEK1/2, ERK1/2, Src and Akt. Consistent with our hypothesis, active form of phosphorylated MEK1/2 and ERK1/2 was significantly decreased while total ERK 1/2 was not altered by αAL14 treatment (Fig. 6B). In addition, αAL14 inhibited activation of Src and FAK (Fig. 6C), Akt and mTOR (Fig. 6D) in a dose-dependent manner, and most of the factors we examined were affected with statistical significance at concentration of >15 µM. Altered localization of phosphorylated ERK1/2, FAK and Akt verified regulatory effects of αAL14 on these three factors (Fig. 7B-D). Taken together, our results indicate that αAL14 provokes its anti-angiogenic activity through downregulating the activation of VEGFR2-mediated downstream signaling pathway in HUVECs.

Effects of αAL14 on factors for actin polymerization in HUVECs. As actin polymerization is an essential step in

Figure 7. Effects of αAL14 on distribution of phosphorylated VEGFR2, ERK1/2 and FAK. HUVECs were treated with 15 µM αAL14 for 30 min. After incubation, cells were assessed with phosphorylated VEGFR2, ERK1/2 or FAK. Images were taken by confocal microscope. (A) Distribution of phospho-VEGFR2 was changed by αAL14 (scale bar, 10 µm). (B) Translocation of ERK1/2 was decreased by αAL14 (scale bar, 20 µm). (C) FAK activity on cell membrane was decreased by αAL14 (scale bar, 10 µm). (D) Phosphorylated Akt was decreased in response to αAL14 treatment (scale bar, 20 µm).
endothelial cell migration, we investigated whether \( \alpha \text{AL14} \) has regulatory effect on actin polymerization-related factors Rho GTPase. Although \( \alpha \text{AL14} \) inhibited Rac1 and Cdc42, Rac1 was much effectively downregulated than Cdc42. In contrast, RhoA was not affected in \( \alpha \text{AL14} \)-treated condition (Fig. 8). Thus, we hypothesized that \( \alpha \text{AL14} \) is capable of regulating lamellipodia because Rac1 is involved in the formation of lamellipodia at the edge of cells (9). \( \alpha \text{AL14} \) relocated Rac1 away from cell membrane where lamellipodia formed (Fig. 8B), and suppressed expression level of Arp2/3 and WAVE2 (Fig. 8C) which are activated by Rac1 to extend lamellipodium at cell membrane (25). Taken together, our results demonstrate that \( \alpha \text{AL14} \) may induce the disorganization of lamellipodium extension via impairing Rac1 signaling in HUVECs.

**Figure 8.** Effects of \( \alpha \text{AL14} \) on components related to cytoskeleton organization. (A and C) \( \alpha \text{AL14} \) suppressed expression of components related with lamellipodia formation. HUVECs were treated with \( \alpha \text{AL14} \) for 24 h. Protein expression levels of Rac1, cdc42, RhoA, Arp2/3 and WAVE2 were detected by western blot analysis. Each column represents the mean ± SD (n=3), \( p<0.001 \). (B) \( \alpha \text{AL14} \) changed the distribution of Rac1 in HUVECs. HUVECs were treated with \( \alpha \text{AL14} \) for 24 h. In immunofluorescence staining, the cells were evaluated with Rac1. Images were taken by confocal microscope (scale bar, 10 \( \mu \text{m} \)).

**Effects of \( \alpha \text{AL14} \) on MMPs expression in HUVECs.** Because endothelial cells secret MMPs to gain cellular motility by degrading surrounding ECM, expression level of MMP9, MMP2 and NF-\( \kappa \text{B} \), one of the well-known transcription factors for the transcription of MMP9 and MMP2, were examined. Expression of MMP9 and MMP2 were suppressed by \( \alpha \text{AL14} \) treatment (Fig. 9A). Phosphorylated NF-\( \kappa \text{B} \) were reduced in comparison with control while total form of NF-\( \kappa \text{B} \) was not changed (Fig. 9A). As well as the decrease in protein level of MMP9 and MMP2, decrease in mRNA level was observed in response to \( \alpha \text{AL14} \) treatment (Fig. 9B). Therefore, we suggest that \( \alpha \text{AL14} \) can reduce the expression of MMP9 and MMP2 via suppressing the activation of NF-\( \kappa \text{B} \).

**Discussion**

Amphipathic \( \alpha \)-helical model peptides have been considered as anti-bacterial agents due to their cationic net charge and amphipathic structure (26). In a recent study, Raddum et al demonstrated that seven different designed peptides based on AnxA2 exhibited anti-angiogenic effects on capillary-like network formation in co-culture system of HUVECs and smooth muscle cells. As D1-P2 peptide including \( \alpha \)-helical conformational structures tended to exert more significant
inhibitory effect on formation of capillary-like networks rather than others (6) we expected that αAL14 which is assumed to contain α-helical structure has similar effects on endothelial cells. Moreover, there have been efforts to develop endogenous

peptides that can penetrate into target cells across the cell membrane because the peptides have lower toxicity without drawbacks (3,5). Therefore, we focused on identifying effects of the novel model peptide αAL14 on angiogenic processes and its permeability in HUVECs. With negative effects of αAL14 on tube formation in HUVECs, αAL14 was able to decrease endothelial cell adhesive, migratory and invasive ability at the same range of concentrations that affected tube formation but anti-proliferative effects on HUVECs induced by apoptosis did not exist. It means that αAL14 is more effective in controlling endothelial cell adhesion, migration and invasion rather than its proliferation during angiogenesis.

VEGFR2 has an important role in pathological angiogenesis of which functions are allowed to become a molecular target for treating various diseases. Phosphorylation of VEGFR2 is a central event for activation of VEGF-mediated angiogenic pathways including endothelial cell proliferation and migration (7,27). In our study, as phosphorylation level of VEGFR2 was decreased by αAL14 treatment, we expected that attenuated VEGFR2 can decrease its downstream factors. As we expected, αAL14 inhibited the subsequent downstream factors such as ERK, FAK, and Akt. Because phosphorylated VEGFR2 at Tyr 1175 is directly connected with an activation of MAPK/ERK and PI3K/Akt/mTOR signaling to promote endothelial cell proliferation and migration via several downstream signaling (28-31), our data suggest that, in αAL14-treated HUVECs, angiogenesis can be regulated through the decrease in phosphorylation of VEGFR2.

FAK is an important component in FAK signaling relating to VEGF-induced endothelial cell migration, which can activate itself through phosphorylation at Tyr 397 (32-35). In addition, Jean et al have demonstrated that c-Src activity is required for full activation of FAK by phosphorylating Tyr 576/577 in response to VEGF treatment (36). However, our data show that phosphorylation of FAK at Tyr 397 and 576/577 was diminished by αAL14 treatment except total form of FAK. It demonstrates that αAL14 can inhibit endothelial cell migration, by regulating activation of FAK in HUVECs. In addition, based on the result that the phosphorylation of FAK at 397 was much reduced compared to 576/577, it is suggested that auto-phosphorylation of FAK is affected sensitively to exposure of αAL14 within 30 min.

In order to identify other molecular targets of αAL14 in connection with endothelial cell migration, expression of Rac1, Cdc42 and RhoA (members of Rho GTPases) was evaluated because they have critical roles in actin dynamics to extend cellular protrusion (37-39). While RhoA expression was not altered by αAL14 treatment, the expression of Rac1 and Cdc42 was changed, and Rac1 was more affected than Cdc42. Because both Arp2 and WA VE2 cooperate with Rac1 for formation of lamellipodia (40-42) cellular level of Arp2 and WA VE2 was examined. From our data, we suggest that αAL14 may disorganize formation of lamellipodia, which is caused by the weak signal of Rac1 in HUVECs.

In terms of endothelial cell invasion, enzymatic families of MMPs are involved in endothelial cell invasion (12) and their transcription is regulated by certain transcription factors such as NF-κB (13,43,44). Therefore, our data suggest that the expression level of MMP2 and MMP9 was inhibited by

Figure 9. Effects of αAL14 on expression of MMP2 and MMP9. (A) αAL14 downregulated the expression of MMP2 and MMP9 through inhibiting NF-κB activity. HUVECs were treated with αAL14 for 24 h and protein expression levels of MMP2, MMP9, NF-κB and phospho-NF-κB were detected by western blot analysis. All statistical data represent mean ± SD (n=3), *p<0.001. (B) mRNA levels of MMP2 and MMP9 were evaluated by RT-PCR. Data represent mean ± SD (n=3), *p<0.001.
αAL14 through attenuating the activation of their transcription factor NF-κB.

Although rapid entry of αAL14 was observed, its internalization mechanism is not clear. However, we can suppose how αAL14 is transferred through the cell membrane. The improvement on internalization of αAL14 at higher temperature indicates that its entry into cells might be mediated by endocytosis, interacting cell membrane receptors. Because several studies have described that the peptides which can easily penetrate into cells at higher temperature rather than lower temperature are entered through receptor-mediated endocytosis. Furthermore, α-helical structure in peptides has an important role in recognition between peptides and cell receptors (45-47). Therefore, we suggest that the internalization of αAL14 containing α-helical structure is connected with receptor-mediated endocytic process of VEGFR2, at least in part, in HUVECs.

In conclusion, we confirmed that the novel model peptide αAL14 penetrated into endothelial cells and regulated various VEGFR2-mediated signaling such as MAPK/ERK, Akt and FAK within relatively short time. αAL14 controlled not only Rac1 and but also Arp2/3 and WAVE2, leading to decrease in cell migration. In addition, decreased expression of MMP2 and MMP9 resulted in inhibition of cell invasion in HUVECs with αAL14 treatment for a relative long time. Therefore, αAL14 may possess two features in the regulation of angiogenesis. One is that αAL14 can inactivate VEGFR2-mediated signaling with preferential internalization into the cytoplasm in a short period of time. The other is maintaining its anti-angiogenic effects by suppressing several factors involved in endothelial cell migration and invasion with broad distribution in cytoplasm and nucleus in HUVECs. Based on these data, we propose that αAL14 has the potential for being developed as a new angiogenesis inhibitor.

Acknowledgements

This study was supported by a grant from the Korea Ministry of Environment (MOE) as ‘Eco-innovation Program (201300030002)’.

References


